The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Now posts as Longholder 1 on the Forum. Not sure what name Nurse posts under...........
Great to have you back with us F32 - we've missed you.
.........and CEPSA looks like it's a "shoe-in". May need some more MMUs!!
As many of you know I have been invested in this Company for a very long time, having been introduced to it by Longholder 1 and The Old Trout. I listened again to the IM presentation and I have to say that I feel more confident than I have done for a long long time. Management seem to finally have a real sense of urgency and focus (about time of course), and determination to get these projects over the line. Feels like some Dominoes are about to fall!!
GLA shipmates.
Or even sign off!
Agreement that trial can be run without static engine testing. Proposal with MSC at present and hope for sing off in the next couple of weeks.
Well, someone's just stuck in £26.5K
.................got the better of me I'm afraid.................bought another 100,000 this lunch time...........shown as a sell of course.
GLA shipmates!!
I know I shouldn't..............I've got far too many already................but I'm beginning to feel I might just have another dip at these prices.
No fool like an old fool? - or brilliant strategist buying at the bottom before 6 months of fantastic RNS's?
7. Tirupati Graphite (TGR): 85p Target 160p
As stated with reference to Cizzle (CIZ), a lot of how a company is regarded on the stock market, at least initially, is how the shares move in the immediate aftermath of the IPO. This has been highlighted in spades with the recent blockbuster float of Bens Creek (BEN). The shares have more than tripled in short order, and there are a lot of happy punters around. Part of what happens in the early stages is dependent on stock market conditions at the time. But common sense dictates that if a company is priced to fly from the get go, the initial share price trajectory is bound to be positive. This was the case with Tirupati, which was listed at near a quarter of its risked valuation, with the stock nearly quadrupling from the 40p zone by the end of H1 2021.
Since then there has been a consolidation, but the green light on a fresh bull run should be on its way given last month’s announcement of the start of commercial production at Vatomina. 2022 is set to move the fundamental dial at TGR: current Madagascar production is 12,000 tpa, expected to reach 30,000 tpa by the middle of next year, and then targets to hit 84,000 tpa by the end of 2024. Production is set to be the near term driver for the stock, with aspects such as its Aluminium Composite and potential tie ins with blue chip companies thrown in the mix as icing on the cake to boost sentiment towards the company going forward. Finally, like many other companies in this list, the passion of the management, in this case from Executive Chairman Shishir Poddar, who is in many ways, Mr Graphite, should never be under-estimated.
1. Eurasia (EUA): 24.5p Target 50p
It has to be admitted that Eurasia was not necessarily going to be top of the 2022 list. The main reason for this is that the company already made its point as far as the bulls were concerned in 2020 when it came back from (unnecessary) suspension. However, it would appear that the court of Twitter, and private investors in general, regard this is a top play for 2022. While this is not necessarily a good indication of whether a company is capable of greatness, I would suggest that there are nevertheless plenty of positive factors to look at. The simplest one is that this is now a £700m company, having been up to £1bn at best so far. Despite all the mudslinging, distortion, character assassination and omission of the bears, EUA has become a mid-tier mining company, and given progress made in 2021, arguably the top tier in its space within the mining sector. I would venture to suggest that if it were not for the waiting game as far as M&A here and the slurs, its market cap would be well north of £1bn currently. Indeed, in many ways the heavy lifting here has already been done, with or without M&A. EUA has not only de-risked via this process, while we have been waiting, the latest Hydrogen and Ammonia projects JV have arguably made it a win-win whatever happens on the corporate action front.
Interestingly enough, it should be noted over 2021 the shares remained at the same starting price despite the flow of significant fundamental water having flowed under the bridge. For instance, the JV with Rogeo consisted of 104.6Moz of Platinum equivalent, and there have been a significant increases and upgrades in mining areas and assets across the enlarged portfolio. EUA will also be a significant Nickel player, and is clearly arm in arm with the Russian State’s mining strategy to propel this further. But above all, Eurasia has shown itself to be a proactive and aggressive player in its space. It could have just sat back waiting for a buyer. Instead, we have seen one of the most active examples of company building in the mining space in recent years, and is fully funded to execute the multi-pronged strategy in 2022 and beyond with minimal dilution. As things stand a sale would merely be the icing on the cake.
4. Open Orphan (ORPH): 23p Target 50p
While it has been a decent year for blue chips on the London market, for the small cap space it has been evident to date that investors have not been getting as much bang for their buck. Just how much reticence there has been was underlined by the recent newsflow from Open Orphan, the specialist contract research and vaccine / antiviral testing group. Going into 2021 the company was one of the stars of its space, given the way that it entered it just as the pandemic began and a light was shined on its business model. What has been interesting is that between November 15 and December 21, the company announced no less than four contract wins amounting to some £20m in value, plus Imutex Vaccine results and positive results from a Flu human challenge study. While the shares may be up some 15% over the period, this amount of fundamental fireworks on a £150m market cap company should and probably will be rewarded in terms of market cap during 2022. This is especially so considering the way that demand for OPRH’s services looks to be accelerating rapidly, and the company has stated it can scale up capacity with ease. In addition, we have the ongoing prospect of spin offs from Open Orphan to maximise shareholder value, of which the first, Poolbeg Pharma (POLB) appears set to make headway over 2022.
3. DeepVerge (DVRG): 24.5p Target 50p
As has been mentioned with reference to East Imperial (EISB), “the next” this or that is a common way of describing growth companies. Perhaps in the case of DeepVerge it would be the case that the company would be on a much higher valuation if it had an obvious peer comparison. However, CEO Gerard Brandon’s brainchild is a unique proposition. I suppose if one stretched things one would like to see DVRG spin off companies like Open Orphan (ORPH) has and should continue to do, but that is where the comparison ends. Brandon’s speciality is to turn around struggling companies. Of course, the skill is to identify which companies to turnaround and then to see them flourish. This is not a commonly held skill. Also, it is not easy to get your timing right on such deals. However, he hit the zeitgeist with Modern Water, and the rest of the vertically integrated company is also on the money in terms of its artificial intelligence, clinical research, medical device and life science offering. One of the sad aspects of the London market as compared to the US is that away from the resources space, valuations especially in the new economy tend to be far less than they would be in the US. Typically, one could add a zero to the market cap to get the equivalent Stateside market cap. In the case of DVRG, it currently stands on £50m, a seemingly ridiculous valuation given the offering it has on a fundamental basis. Unusually, this is a company that spans markets with clients from Governments, to B2B, and via Labskin, the consumer area, with all aspects scalable on a global basis.
In at number 4.
https://www.**********.co.uk/articles/traders-cafe-with-zak-mir-the-top-20-countdown-for-2022-4-to-1-2cbc4a2
Even better -number 3!!
In at number 4
https://www.**********.co.uk/articles/traders-cafe-with-zak-mir-the-top-20-countdown-for-2022-4-to-1-2cbc4a2
Happy New Year shipmates.
What came through again and again at the AGM is that Jason and the Board are extremely confident about delivering in 2022. Yes, I know we've heard all this before but I, for one, really think 2022 will be our year.
Fingers and everything else crossed.
GLA
https://twitter.com/QFIPLC/status/1473710659770716169
Posted 1 hour ago - not sure if there is any significance with the timing. We can but hope!
GLA